Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Originator

Almen, T.|Nyegaard

1

Pfizer

420

Eli Lilly

237

Merck

216

GlaxoSmithKline

193

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Previously Marketed

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1978

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Spinal cord disease

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Diagnostic

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Non-penetrant

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

1

ChEMBL

1

DRUG BANK

1

DRUG CENTRAL

1

ECHA (EC/EINECS)

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

VARIOUS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

CONTRAST MEDIA

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

X-RAY CONTRAST MEDIA, IODINATED

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Watersoluble, nephrotropic, low osmolar X-ray contrast media

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 1 of 1 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

METRIZAMIDE

RHH3W8F1CO

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1978

Class (Stereo):

CHEMICAL (ABSOLUTE)

Conditions:

Spinal cord disease

Metrizamide is a glucosamine derivative of metrazoic acid, used as a contrast medium for myelography. Metrizamide is no longer marketed in the US.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1